Folketrygdfondet Novo Nordisk A S Transaction History

Folketrygdfondet

$4.49 Billion
Q1 2024

A detailed history of Folketrygdfondet transactions in Novo Nordisk A S stock. As of the latest transaction made, Folketrygdfondet holds 8,756,034 shares of NVO stock, worth $1.18 Billion. This represents 25.05% of its overall portfolio holdings.

Number of Shares

8,756,034

Previous 8,631,264 1.45%

Holding current value

$1.18 Billion

Previous $893 Million 25.91%

% of portfolio

25.05%

Previous 18.58%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 15, 2024	BUY	$102.11 - $135.92 $12.7 Million - $17 Million	124,770 Added 1.45%	8,756,034 $1.12 Billion
Q4 2023 Feb 08, 2024	BUY	$87.78 - $105.45 $19.8 Million - $23.8 Million	225,822 Added 2.69%	8,631,264 $893 Million
Q3 2023 Nov 14, 2023	BUY	$90.94 - $199.54 $371 Million - $813 Million	4,074,407 Added 94.07%	8,405,442 $764 Million
Q2 2023 Aug 11, 2023	BUY	$155.98 - $172.65 $12.6 Million - $14 Million	81,045 Added 1.91%	4,331,035 $701 Million
Q1 2023 Apr 20, 2023	SELL	$132.34 - $159.14 $4.61 Million - $5.55 Million	-34,868 Reduced 0.81%	4,249,990 $676 Million

Q4 2022 Feb 10, 2023	BUY	$102.55 - $135.33 $2.28 Million - $3 Million	22,199 Added 0.52%	4,284,858 $580 Million
Q3 2022 Oct 28, 2022	BUY	$95.28 - $116.93 $11.4 Million - $14 Million	119,781 Added 2.89%	4,262,659 $425 Million
Q2 2022 Aug 08, 2022	BUY	$103.24 - $121.81 $379 Million - $447 Million	3,666,475 Added 769.62%	4,142,878 $462 Million
Q1 2022 May 06, 2022	SELL	$93.1 - $112.54 $367 Million - $444 Million	-3,943,480 Reduced 89.22%	476,403 $52.9 Million
Q4 2021 Feb 01, 2022	SELL	$95.88 - $117.08 $28.3 Million - $34.6 Million	-295,634 Reduced 6.27%	4,419,883 $495 Million
Q2 2021 Aug 04, 2021	BUY	$67.66 - $84.76 $31.5 Million - $39.5 Million	466,107 Added 10.97%	4,715,517 $395 Million
Q1 2021 May 04, 2021	SELL	$67.06 - $75.82 $94.9 Million - $107 Million	-1,414,792 Reduced 24.98%	4,249,410 $286 Million
Q4 2020 Jan 29, 2021	BUY	$63.89 - $73.8 $9 Million - $10.4 Million	140,792 Added 2.55%	5,664,202 $396 Million
Q2 2020 Aug 07, 2020	SELL	$58.54 - $67.94 $13.1 Million - $15.2 Million	-223,012 Reduced 3.88%	5,523,410 $362 Million
Q1 2020 May 13, 2020	BUY	$49.46 - $64.78 $101,096 - $132,410	2,044 Added 0.04%	5,746,422 $346 Million
Q3 2019 Nov 12, 2019	BUY	$47.54 - $53.43 $23.8 Million - $26.7 Million	500,000 Added 9.53%	5,744,378 $297 Million
Q2 2019 Aug 14, 2019	SELL	$46.79 - $52.47 $384,286 - $430,936	-8,213 Reduced 0.16%	5,244,378 $268 Million
Q1 2019 May 09, 2019	SELL	$46.36 - $52.63 $22.3 Million - $25.3 Million	-480,000 Reduced 8.37%	5,252,591 $275 Million
Q4 2018 Feb 13, 2019	BUY	$41.54 - $47.25 $1.61 Million - $1.83 Million	38,642 Added 0.68%	5,732,591 $264 Million
Q1 2018 Apr 30, 2018	SELL	$48.49 - $58.14 $57.1 Million - $68.5 Million	-1,178,094 Reduced 17.14%	5,693,949 $280 Million
Q4 2017 Feb 13, 2018	SELL	$47.53 - $53.73 $16.4 Million - $18.5 Million	-345,000 Reduced 4.78%	6,872,043 $369 Million
Q3 2017 Nov 09, 2017	BUY	$41.15 - $49.22 $12.5 Million - $14.9 Million	302,851 Added 4.38%	7,217,043 $348 Million
Q2 2017 Aug 09, 2017	BUY	N/A	6,914,192	6,914,192 $297 Million

Others Institutions Holding NVO

# of Institutions

1,851

Shares Held

309M

Call Options Held

5.29M

Put Options Held

4.93M

View Full List

About NOVO NORDISK A S

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $305B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

More about NVO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Folketrygdfondet, based on Form 13F filings with the SEC.

News

Stay updated on Folketrygdfondet with notifications on news.

Account

Folketrygdfondet Novo Nordisk A S Transaction History